Translocation of species, populations, or genotypes beyond their historic ranges (i.e., assisted migration [AM]) is an oft‐debated climate adaptation strategy. Well‐intentioned AM actions could alter disease dynamics for target species and recipient sites, resulting in unanticipated detrimental economic and ecological impacts. Although disease risks are occasionally mentioned in AM debates, current regulations or best practices that reduce or mitigate these complex risks are generally lacking in North America. We use the “Disease Triangle”, a foundational framework in pathology, to illustrate pathways through which AM may impact disease emergence, to identify knowledge gaps, and to suggest best practices to reduce disease risks. We highlight empirical examples in which altering pathogen distributions, host communities, and environment have historically resulted in costly and ecologically damaging diseases in plants. Although guidelines to reduce disease risks in AM are generally lacking, policies governing endangered species, invasive species, and disease management can provide starting points for a more comprehensive policy. We use examples from the United States to identify key strengths and weaknesses that can inform regulations to reduce disease risks associated with AM. We argue that consideration of disease motivates policy development that incorporates improved risk assessments, agency coordination, and accountability mechanisms.

中文翻译：

---

通过辅助迁移扩大植物病害风险

物种，种群或基因型的迁移超出其历史范围（即辅助迁移[AM]）是一种经常争论的气候适应策略。精心设计的AM行动可能会改变目标物种和受体部位的疾病动态，从而导致意想不到的不利经济和生态影响。尽管在AM辩论中偶尔会提到疾病风险，但北美通常缺乏减少或减轻这些复杂风险的现行法规或最佳实践。我们使用“疾病三角”（病理学的基础框架）来说明增材制造可能影响疾病出现的途径，确定知识差距，并提出降低疾病风险的最佳实践。我们重点介绍了改变病原体分布，寄主社区，历史上，环境和环境已导致植物中代价高昂且对生态造成破坏的疾病。尽管通常缺乏降低AM中疾病风险的指南，但有关濒危物种，入侵物种和疾病管理的政策可以为更全面的政策提供起点。我们使用来自美国的示例来确定关键优势和劣势，这些优势和劣势可以为法规减少与AM相关的疾病风险提供信息。我们认为，对疾病的考虑会促使制定政策，其中包括改进的风险评估，机构协调和问责机制。疾病管理可以为制定更全面的政策提供起点。我们使用来自美国的示例来确定关键优势和劣势，这些优势和劣势可以为法规减少与AM相关的疾病风险提供信息。我们认为，对疾病的考虑会促使制定政策，其中包括改进的风险评估，机构协调和问责机制。疾病管理可以为制定更全面的政策提供起点。我们使用来自美国的示例来确定关键优势和劣势，这些优势和劣势可以为法规减少与AM相关的疾病风险提供信息。我们认为，对疾病的考虑会促使制定政策，其中包括改进的风险评估，机构协调和问责机制。